MICROBIOME MODIFICATION AND IMPROVEMENT OF SIGNS AND SYMPTOMS OF COVID-19: ILEOCOLONIC-RELEASE NICOTINAMIDE IN A PROSPECTIVE, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED TRIAL

Stefan Schreiber  ^{1, 2}     Georg H. Waetzig  ^{1, 2, 3}     Corinna Geisler  ^{1, 2}     Kristina Schlicht  ^{1, 2}     Sina Franzenburg  ⁴     Víctor A. López-Agudelo  ^{1, 2}     Romina di Giuseppe  ²     Daniel Pape  ²     Thomas Bahmer  ²     Michael Krawczak  ²     Elisabeth Kokott  ²     Oliver Harzer  ⁵     Jan Kramer  ⁶     Tammo von Schrenck  ⁷     Felix Sommer  ^{1, 2}     Helena U. Zacharias  ⁸     Jan Heyckendorf  ⁸     Konrad Aden  ^{1, 2}     Regina Hollweck  ⁹     Matthias Laudes  ^{1, 2}     Philip Rosenstiel  ^{1, 2    
1} University Medical Center Schleswig-Holstein, Kiel, Germany
² Kiel University, Kiel, Germany
³ CONARIS Research Institute AG, Kiel, Germany
⁴ Competence Network Intestinal Diseases, Kiel, Germany
⁵ Bioscientia Healthcare GmbH, Ingelheim, Germany
⁶ LADR GmbH MVZ Dr. Kramer & Kollegen, Geesthacht, Germany
⁷ Labor Dr. von Froreich GmbH, Hamburg, Germany
⁸ Peter L. Reichertz Institute for Medical Informatics, Hanover, Germany
⁹ Novustat GmbH, Wollerau, Switzerland

Session
PP 09 COVID-19 (Posters)

Conference
UEG Week 2023

Citation
United European Gastroenterology Journal 2023; 11 (Supplement 8)